- Home
- IDAI vs HOTH Comparison
IDAI vs HOTH Comparison
Compare IDAI & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDAI
- HOTH
- Stock Information
- Founded
- IDAI 2016
- HOTH 2017
- Country
- IDAI United States
- HOTH United States
- Employees
- IDAI N/A
- HOTH N/A
- Industry
- IDAI Computer Software: Prepackaged Software
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- IDAI Technology
- HOTH Health Care
- Exchange
- IDAI Nasdaq
- HOTH Nasdaq
- Market Cap
- IDAI 9.7M
- HOTH 8.3M
- IPO Year
- IDAI N/A
- HOTH 2019
- Fundamental
- Price
- IDAI $2.68
- HOTH $1.06
- Analyst Decision
- IDAI
- HOTH Strong Buy
- Analyst Count
- IDAI 0
- HOTH 4
- Target Price
- IDAI N/A
- HOTH $4.75
- AVG Volume (30 Days)
- IDAI 132.9K
- HOTH 673.3K
- Earning Date
- IDAI 03-31-2025
- HOTH 03-27-2025
- Dividend Yield
- IDAI N/A
- HOTH N/A
- EPS Growth
- IDAI N/A
- HOTH N/A
- EPS
- IDAI N/A
- HOTH N/A
- Revenue
- IDAI $2,160,186.00
- HOTH N/A
- Revenue This Year
- IDAI N/A
- HOTH N/A
- Revenue Next Year
- IDAI $139.59
- HOTH N/A
- P/E Ratio
- IDAI N/A
- HOTH N/A
- Revenue Growth
- IDAI N/A
- HOTH N/A
- 52 Week Low
- IDAI $0.15
- HOTH $0.58
- 52 Week High
- IDAI $8.96
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- IDAI 41.42
- HOTH 42.86
- Support Level
- IDAI $2.43
- HOTH $1.01
- Resistance Level
- IDAI $3.22
- HOTH $1.09
- Average True Range (ATR)
- IDAI 0.30
- HOTH 0.08
- MACD
- IDAI -0.14
- HOTH -0.02
- Stochastic Oscillator
- IDAI 23.36
- HOTH 25.93
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.